Stock listing

Frankfurt:08D Mirum Pharmaceuticals, Inc. Aktie

German listing (Frankfurt) of Mirum Pharmaceuticals, Inc. · home listing NASDAQ:MIRM

Follow Mirum Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · FWB:08D

€82.00 EUR -3.50 (-4.1%)

Close on Nov 6, 2026

Past year +39.6% · daily closes, Nov 6, 2025 – Nov 6, 2026, adjusted for splits
Day range
€81.06 – €82.59 EURNov 6, 2026
Market cap
€5.32B EURAt the close on Nov 6, 2026 · price × 64.93M shares outstanding
52-week range
€52.24 – €110.55 EURLowest and highest trades, Nov 7, 2025 – Nov 6, 2026
Traded on an average day
€2,505 EURMedian day 0 shares · 44 days with no trades · last 3 months, Aug 6, 2026 – Nov 6, 2026
Mirum Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:MIRM · Home$93.72 USD+0.18 (+0.2%)722,713$93.14$95.59$91.18$93.54Close on Nov 6, 2026
Frankfurt:08D€82.00 EUR-3.497 (-4.1%)—€81.53€82.59€81.06€85.50Close on Nov 6, 2026

Daily closes

Last 3 months, Aug 6, 2026 – Nov 6, 2026 · FWB:08D · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€82.00-3.497-4.1%€81.53€82.59€81.060
€85.50+1.198+1.4%€85.60€85.60€84.35101
€84.30+10.16+13.7%€78.06€84.62€76.66101
€74.14+0.14+0.2%€74.27€74.29€73.800
€74.00-1.792-2.4%€74.01€74.41€73.790
€75.79-2.433-3.1%€75.98€76.03€75.5418
€78.22+2.841+3.8%€75.80€78.31€75.2320
€75.38+2.254+3.1%€74.72€75.48€74.0836
€73.13+1.379+1.9%€73.57€73.60€72.38122
€71.75-0.559-0.8%€70.77€71.77€70.09122
€72.31-0.655-0.9%€72.64€72.64€72.202
€72.96-0.945-1.3%€73.17€73.69€72.880
€73.91+2.637+3.7%€73.93€74.16€73.520
€71.27+1.265+1.8%€71.62€71.71€71.130
€70.00-1.665-2.3%€70.29€70.39€69.950
€71.67+2.642+3.8%€71.90€72.21€71.570
€69.03-0.0290.0%€69.56€70.41€68.760
€69.06-6.268-8.3%€69.12€69.12€68.920
€75.32-2.447-3.1%€75.41€75.41€75.2826
€77.77+6.425+9.0%€74.76€77.98€74.75241
€71.35+0.088+0.1%€71.53€71.63€71.0620
€71.26+2.835+4.1%€70.94€71.66€70.4515
€68.42-1.714-2.4%€68.69€68.78€68.150
€70.14-2.662-3.7%€70.72€70.72€70.080
€72.80-0.877-1.2%€73.34€75.65€72.4415
€73.68-0.728-1.0%€73.72€73.72€73.3165
€74.40+0.198+0.3%€74.16€74.48€73.960
€74.21-1.307-1.7%€75.07€76.74€73.980
€75.51-2.691-3.4%€76.12€76.67€75.410
€78.20+0.614+0.8%€78.25€78.25€77.98324
€77.59+0.846+1.1%€77.54€77.80€76.9916
€76.74-1.568-2.0%€76.84€77.04€76.740
€78.31+0.178+0.2%€78.59€79.51€78.220
€78.13-0.137-0.2%€78.60€79.00€78.120
€78.27-5.846-6.9%€78.95€79.17€78.010
€84.12+0.31+0.4%€84.23€84.47€84.090
€83.81+3.958+5.0%€83.82€83.82€83.710
€79.85-0.711-0.9%€79.85€80.04€79.400
€80.56-2.291-2.8%€81.13€81.17€80.35158
€82.85-2.361-2.8%€82.95€83.09€82.660
€85.21+2.473+3.0%€85.41€85.41€84.70200
€82.74-1.067-1.3%€83.81€83.92€82.730
€83.81+0.126+0.2%€84.04€84.41€83.490
€83.68-0.775-0.9%€83.82€84.52€82.700
€84.45+0.247+0.3%€84.51€84.51€84.130
€84.21-0.143-0.2%€85.35€85.44€83.62106
€84.35+1.248+1.5%€84.37€84.37€83.820
€83.10+1.023+1.2%€83.30€83.75€82.910
€82.08-0.563-0.7%€82.17€83.32€81.320
€82.64-1.256-1.5%€82.67€82.97€81.610
€83.90+1.487+1.8%€84.15€84.53€83.83106
€82.41-0.318-0.4%€82.50€82.55€82.370
€82.73+1.903+2.4%€82.73€82.73€81.950
€80.83+0.419+0.5%€81.80€82.15€80.220
€80.41-0.829-1.0%€80.42€80.44€80.340
€81.24-3.487-4.1%€81.24€81.47€81.1554
€84.72+0.336+0.4%€85.87€86.40€84.470
€84.39+0.364+0.4%€84.52€84.72€84.370
€84.02-1.157-1.4%€84.07€84.10€83.480
€85.18+1.691+2.0%€85.22€85.22€84.370
€83.49+0.486+0.6%€83.60€83.60€82.800
€83.00-0.159-0.2%€83.74€84.06€82.960
€83.16+0.429+0.5%€83.29€83.29€82.180
€82.73-2.085-2.5%€83.54€83.59€82.140
€84.82+5.41+6.8%€84.89€85.34€84.710
€79.41-4.092-4.9%€79.48€79.92€78.5636
€83.50-5.088-5.7%€83.50€83.50€83.50200
Ticker
Frankfurt:08D
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Replays

  • Mirum Pharmaceuticals (NASDAQ:MIRM) Q3 2026 Earnings Call

    Tue, Nov 03, 2026 · 4:30 PM ET

    Watch Transcript

  • Mirum Pharmaceuticals (NASDAQ:MIRM) Q2 2026 Earnings Call

    Wed, Aug 05, 2026 · 4:30 PM ET

    Watch Transcript

  • Mirum Pharmaceuticals (NASDAQ:MIRM) Q1 2026 Earnings Call

    Wed, May 06, 2026 · 4:30 PM ET

    Watch Transcript

Latest news

Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Nov 3, 2026

Closed €84.30 (+13.7%) on Nov 4, 2026

Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD’s The Liver Meeting® 2026

Nov 2, 2026

Closed €74.00 (-2.4%) on Nov 2, 2026

Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026

Oct 27, 2026

Closed €75.38 (+3.1%) on Oct 28, 2026

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva

Oct 26, 2026

Closed €71.75 (-0.8%) on Oct 26, 2026

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Oct 21, 2026

Closed €72.96 (-1.3%) on Oct 22, 2026

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 15, 2026

Closed €71.67 (+3.8%) on Oct 16, 2026

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

Oct 12, 2026

Closed €77.77 (+9.0%) on Oct 12, 2026

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

Sep 28, 2026

Closed €78.20 (+0.8%) on Sep 28, 2026

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026

Sep 27, 2026

Closed €78.20 (+0.8%) on Sep 28, 2026

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Sep 25, 2026

Closed €78.20 (+0.8%) on Sep 28, 2026

All Mirum Pharmaceuticals, Inc. news

Financings

  • Private placement of common stock and pre-funded warrants

    Jan 26, 2026

    Closed: US$200M raised · US$68.48 a share · Morgan Stanley & Co. LLC +4

    Dealers: Morgan Stanley & Co. LLC, Leerink Partners LLC, Cantor Fitzgerald & Co., Raymond James & Associates, Inc., Citizens JMP Securities, LLC

    Use of proceeds: To support clinical development and commercial activities following the acquisition of brelovitug in HDV

    Announced Dec 8, 2025 · Closed Jan 26, 2026

  • Private placement of common stock

    Jan 26, 2026

    Closed: US$68.5M raised · US$68.48 a share

    Buyers: TCGX (1,000,000 shares of common stock)

    Use of proceeds: To support clinical development and commercial activities following the acquisition of brelovitug in HDV

    Announced Dec 19, 2025 · Closed Jan 26, 2026

Read by 6ix AI from the company's releases

Decks

Mirum Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
40 in the last 12 months · 206 in all · newest Nov 3, 2026 · oldest 2019
Calls
21 calls with a replay · 21 with a transcript · latest Nov 3, 2026
Decks
27 decks · latest Oct 12, 2026

Where Mirum Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:MIRM · Home listingNASDAQUnited StatesUSD
Tradegate:08DTradegateGermanyEUR
gettex:08DgettexGermanyEUR
Lang & Schwarz:A2PM29Lang & SchwarzGermanyEUR
Dusseldorf:08DDusseldorfGermanyEUR
LS Exchange:A2PM29LS ExchangeGermanyEUR
BMV:MIRMBMVMexicoMXN
Frankfurt:08D · This pageFrankfurtGermanyEUR
BIVA:MIRMBIVAMexicoMXN
BOATS:MIRMBOATSUnited StatesUSD
Hamburg:08DHamburgGermanyEUR
Munich:08DMunichGermanyEUR
Stuttgart:08DStuttgartGermanyEUR
Hanover:08DHanoverGermanyEUR
Xetra:08DXetraGermanyEUR

Log in to ask 6ix AI your own questions about Mirum Pharmaceuticals, Inc.